J
Jeanine E. Ballard
Researcher at Merck & Co.
Publications - 26
Citations - 925
Jeanine E. Ballard is an academic researcher from Merck & Co.. The author has contributed to research in topics: In vivo & Calcium channel. The author has an hindex of 15, co-authored 24 publications receiving 771 citations. Previous affiliations of Jeanine E. Ballard include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
Thomayant Prueksaritanont,Xiaoyan Chu,Christopher R. Gibson,Donghui Cui,Ka Lai Yee,Jeanine E. Ballard,Tamara D. Cabalu,Jerome Hochman +7 more
TL;DR: The need for conducting DDI studies on a case-by-case basis using a holistic scientifically based interrogative approach is conveyed and the need for additional research to fill in knowledge gaps in these areas where the science is rapidly evolving to better ensure the safety and efficacy of new therapeutic agents is communicated.
Journal ArticleDOI
Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist.
William D. Shipe,James C. Barrow,Zhi Qiang Yang,Craig W. Lindsley,Craig W. Lindsley,F. Vivien Yang,Schlegel Kelly-Ann,Youheng Shu,Kenneth E. Rittle,Mark G. Bock,Mark G. Bock,George D. Hartman,Cuyue Tang,Jeanine E. Ballard,Yuhsin Kuo,Emily D. Adarayan,Thomayant Prueksaritanont,Matthew M. Zrada,Victor N. Uebele,Cindy E. Nuss,Thomas M. Connolly,Scott M. Doran,Steven V. Fox,Richard L. Kraus,Michael J. Marino,Michael J. Marino,Valerie Kuzmick Graufelds,Hugo M. Vargas,Hugo M. Vargas,Patricia B. Bunting,Martha Hasbun-Manning,Rose M. Evans,Kenneth S. Koblan,John J. Renger +33 more
TL;DR: Structural modification of the p Piperidine leads 1 and 2 afforded the fluorinated piperidine ( S)- 5, a potent and selective antagonist that displayed in vivo CNS efficacy without adverse cardiovascular effects.
Journal ArticleDOI
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
Zhi-Qiang Yang,James C. Barrow,William D. Shipe,Kelly-Ann S. Schlegel,Youheng Shu,F. Vivien Yang,Craig W. Lindsley,Craig W. Lindsley,Kenneth E. Rittle,Mark G. Bock,Mark G. Bock,George D. Hartman,Victor N. Uebele,Cindy E. Nuss,Steven V. Fox,Richard L. Kraus,Scott M. Doran,Thomas M. Connolly,Cuyue Tang,Jeanine E. Ballard,Yuhsin Kuo,Emily D. Adarayan,Thomayant Prueksaritanont,Matthew M. Zrada,Michael J. Marino,Michael J. Marino,Valerie Kuzmick Graufelds,Anthony G. DiLella,Ian J. Reynolds,Hugo M. Vargas,Hugo M. Vargas,Patricia B. Bunting,Richard Woltmann,Michael M. Magee,Kenneth S. Koblan,John J. Renger +35 more
TL;DR: Compound 30 demonstrated a robust reduction in the number and duration of seizures at 33 nM plasma concentration, with no cardiovascular effects at up to 5.6 microM, and is a useful tool for probing the effects of T-type calcium channel inhibition.
Journal ArticleDOI
Antagonism of T-type calcium channels inhibits high-fat diet–induced weight gain in mice
Victor N. Uebele,Anthony L. Gotter,Cindy E. Nuss,Richard L. Kraus,Scott M. Doran,Susan L. Garson,Duane R. Reiss,Yuxing Li,James C. Barrow,Thomas S. Reger,Zhi Qiang Yang,Jeanine E. Ballard,Cuyue Tang,Joseph M. Metzger,Sheng Ping Wang,Kenneth S. Koblan,John J. Renger +16 more
TL;DR: What is believed to be a previously unknown role for T-type calcium channels in the regulation of sleep and weight maintenance is identified and the potential for a novel therapeutic approach to treating obesity is suggested.
Journal ArticleDOI
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.
Harold G. Selnick,J. Fred Hess,Cuyue Tang,Kun Liu,Joel B. Schachter,Jeanine E. Ballard,Jacob Marcus,Daniel J. Klein,Xiaohai Wang,Michelle Pearson,Mary J. Savage,Ramesh Kaul,Tong-Shuang Li,David J. Vocadlo,Yuanxi Zhou,Yongbao Zhu,Changwei Mu,Yaode Wang,Wei Zhongyong,Chang Bai,Joseph L. Duffy,Ernest J. McEachern +21 more
TL;DR: The medicinal chemistry and pharmacological studies that led to the identification of (3aR,5S,6S,7R, 7aR)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5H-pyrano[3,2-d]thiazole- 6,7-diol 42 (MK-8719) are described.